CN102498111A - 作为Bcl-2家族蛋白抑制剂用于癌症的治疗的磺酰胺化合物 - Google Patents
作为Bcl-2家族蛋白抑制剂用于癌症的治疗的磺酰胺化合物 Download PDFInfo
- Publication number
- CN102498111A CN102498111A CN2010800396704A CN201080039670A CN102498111A CN 102498111 A CN102498111 A CN 102498111A CN 2010800396704 A CN2010800396704 A CN 2010800396704A CN 201080039670 A CN201080039670 A CN 201080039670A CN 102498111 A CN102498111 A CN 102498111A
- Authority
- CN
- China
- Prior art keywords
- alkylene
- alkyl
- methyl
- unsubstituted
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(C)c1c(C)c(C)*n1 Chemical compound CC(C)(C)c1c(C)c(C)*n1 0.000 description 11
- YPJKFELBVYDYBS-GFCCVEGCSA-N C[C@H](CCN(C)C)CSc1ccccc1 Chemical compound C[C@H](CCN(C)C)CSc1ccccc1 YPJKFELBVYDYBS-GFCCVEGCSA-N 0.000 description 2
- YNABOMIPNXLHAA-BIIKFXOESA-N C/C=C/N1C(CCN2CC(CC3)OC3C2)(CSc2ccccc2)C1 Chemical compound C/C=C/N1C(CCN2CC(CC3)OC3C2)(CSc2ccccc2)C1 YNABOMIPNXLHAA-BIIKFXOESA-N 0.000 description 1
- JSCOSCMQDKXQSB-GBBGHBRZSA-N C/C=C/N[C@H](CCN1CCN(C)CC1)CS/C(/C)=C/C=C Chemical compound C/C=C/N[C@H](CCN1CCN(C)CC1)CS/C(/C)=C/C=C JSCOSCMQDKXQSB-GBBGHBRZSA-N 0.000 description 1
- MJDPQEJNBDLDBJ-HMSMRMQOSA-N CC(/C(/C=C)=C(/C)\c(cc1)ccc1Cl)N(CC1)CCC1N(C)CC(/N=C\C)=C Chemical compound CC(/C(/C=C)=C(/C)\c(cc1)ccc1Cl)N(CC1)CCC1N(C)CC(/N=C\C)=C MJDPQEJNBDLDBJ-HMSMRMQOSA-N 0.000 description 1
- AICUMESJLNUCSL-UHFFFAOYSA-N CC(C)(C)OC(N1CC[n]2c(NS(c(cc3)cc(S(C(C)(F)F)(=O)=O)c3N3C(CCN4CCOCC4)(CSc4ccccc4)C3)(=O)=O)nnc2CC1)=O Chemical compound CC(C)(C)OC(N1CC[n]2c(NS(c(cc3)cc(S(C(C)(F)F)(=O)=O)c3N3C(CCN4CCOCC4)(CSc4ccccc4)C3)(=O)=O)nnc2CC1)=O AICUMESJLNUCSL-UHFFFAOYSA-N 0.000 description 1
- OAHDKKCWDWBWJM-UHFFFAOYSA-N CC(C)(C)OC1OC1NCC(N=[IH])=C Chemical compound CC(C)(C)OC1OC1NCC(N=[IH])=C OAHDKKCWDWBWJM-UHFFFAOYSA-N 0.000 description 1
- FHBVRXRRMMPYHJ-UHFFFAOYSA-N CC(C)CN(CC1)CCC1N(CC1)Cc2c1c(NC)ncn2 Chemical compound CC(C)CN(CC1)CCC1N(CC1)Cc2c1c(NC)ncn2 FHBVRXRRMMPYHJ-UHFFFAOYSA-N 0.000 description 1
- DCYOMQLJQDGYBX-UJMHRVFCSA-N CC(C)COC[C@@H](CCN(C)C)N/C(/C)=C/C=C Chemical compound CC(C)COC[C@@H](CCN(C)C)N/C(/C)=C/C=C DCYOMQLJQDGYBX-UJMHRVFCSA-N 0.000 description 1
- IMIYUEAJSVOXPT-UHFFFAOYSA-N CC(C)c1c(CNC2)c2ncn1 Chemical compound CC(C)c1c(CNC2)c2ncn1 IMIYUEAJSVOXPT-UHFFFAOYSA-N 0.000 description 1
- UIKOCHQEVJSKAW-MRXNPFEDSA-N CC(F)(F)S(c(cc(cc1)S(Nc2c(CCNC3)c3ncn2)(=O)=O)c1N[C@H](CCNC)CSCC=C)(=O)=O Chemical compound CC(F)(F)S(c(cc(cc1)S(Nc2c(CCNC3)c3ncn2)(=O)=O)c1N[C@H](CCNC)CSCC=C)(=O)=O UIKOCHQEVJSKAW-MRXNPFEDSA-N 0.000 description 1
- GGTLUWPDWGKVMO-LJQANCHMSA-N CS(c(cc(cc1)S(NC(N=[IH])=C)(=O)=O)c1N[C@H](CCN1CCOCC1)CSc1ccccc1)(=O)=O Chemical compound CS(c(cc(cc1)S(NC(N=[IH])=C)(=O)=O)c1N[C@H](CCN1CCOCC1)CSc1ccccc1)(=O)=O GGTLUWPDWGKVMO-LJQANCHMSA-N 0.000 description 1
- BUPHELSRJCKPDD-UHFFFAOYSA-N Cc1ncnc(C2)c1CCN2C(CC1)CCN1I Chemical compound Cc1ncnc(C2)c1CCN2C(CC1)CCN1I BUPHELSRJCKPDD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24125109P | 2009-09-10 | 2009-09-10 | |
| US61/241,251 | 2009-09-10 | ||
| PCT/EP2010/063169 WO2011029842A1 (en) | 2009-09-10 | 2010-09-08 | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102498111A true CN102498111A (zh) | 2012-06-13 |
Family
ID=43016684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800396704A Pending CN102498111A (zh) | 2009-09-10 | 2010-09-08 | 作为Bcl-2家族蛋白抑制剂用于癌症的治疗的磺酰胺化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8809352B2 (https=) |
| EP (1) | EP2475661B1 (https=) |
| JP (1) | JP2013504536A (https=) |
| KR (1) | KR20120078715A (https=) |
| CN (1) | CN102498111A (https=) |
| AU (1) | AU2010294292B2 (https=) |
| BR (1) | BR112012005343A2 (https=) |
| CA (1) | CA2772989A1 (https=) |
| EA (1) | EA020586B1 (https=) |
| ES (1) | ES2443845T3 (https=) |
| MX (1) | MX2012003007A (https=) |
| WO (1) | WO2011029842A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023236814A1 (zh) * | 2022-06-10 | 2023-12-14 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG192126A1 (en) * | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| EP2794588A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| JP2015503518A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
| CN105636945B (zh) | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
| JP6223563B2 (ja) | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US10975051B2 (en) * | 2015-08-12 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases |
| EP3936153B1 (en) | 2016-01-11 | 2024-08-21 | Celator Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
| WO2017123616A1 (en) * | 2016-01-11 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| JP7839962B2 (ja) | 2020-04-15 | 2026-04-03 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｂｃｌ－２阻害剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080586A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| CN101039662A (zh) * | 2004-08-20 | 2007-09-19 | 密执安州立大学董事会 | 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用 |
| CN101535280A (zh) * | 2006-11-15 | 2009-09-16 | 健泰科生物技术公司 | 芳基磺酰胺化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| FR2912145B1 (fr) * | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2010
- 2010-09-08 WO PCT/EP2010/063169 patent/WO2011029842A1/en not_active Ceased
- 2010-09-08 CA CA2772989A patent/CA2772989A1/en not_active Abandoned
- 2010-09-08 ES ES10750124.9T patent/ES2443845T3/es active Active
- 2010-09-08 EP EP10750124.9A patent/EP2475661B1/en not_active Not-in-force
- 2010-09-08 CN CN2010800396704A patent/CN102498111A/zh active Pending
- 2010-09-08 US US13/394,525 patent/US8809352B2/en not_active Expired - Fee Related
- 2010-09-08 BR BR112012005343A patent/BR112012005343A2/pt not_active IP Right Cessation
- 2010-09-08 JP JP2012528347A patent/JP2013504536A/ja active Pending
- 2010-09-08 MX MX2012003007A patent/MX2012003007A/es active IP Right Grant
- 2010-09-08 EA EA201200472A patent/EA020586B1/ru not_active IP Right Cessation
- 2010-09-08 KR KR1020127009091A patent/KR20120078715A/ko not_active Withdrawn
- 2010-09-08 AU AU2010294292A patent/AU2010294292B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080586A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| CN101039662A (zh) * | 2004-08-20 | 2007-09-19 | 密执安州立大学董事会 | 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用 |
| CN101535280A (zh) * | 2006-11-15 | 2009-09-16 | 健泰科生物技术公司 | 芳基磺酰胺化合物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023236814A1 (zh) * | 2022-06-10 | 2023-12-14 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012003007A (es) | 2012-04-11 |
| EA201200472A1 (ru) | 2012-10-30 |
| KR20120078715A (ko) | 2012-07-10 |
| EA020586B1 (ru) | 2014-12-30 |
| WO2011029842A1 (en) | 2011-03-17 |
| EP2475661B1 (en) | 2013-10-23 |
| AU2010294292A1 (en) | 2012-03-01 |
| AU2010294292B2 (en) | 2013-07-18 |
| US8809352B2 (en) | 2014-08-19 |
| BR112012005343A2 (pt) | 2016-03-22 |
| US20120165298A1 (en) | 2012-06-28 |
| EP2475661A1 (en) | 2012-07-18 |
| CA2772989A1 (en) | 2011-03-17 |
| JP2013504536A (ja) | 2013-02-07 |
| ES2443845T3 (es) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102498111A (zh) | 作为Bcl-2家族蛋白抑制剂用于癌症的治疗的磺酰胺化合物 | |
| TWI851563B (zh) | 作為免疫調節劑之雜環化合物 | |
| CN103261201B (zh) | 作为trpa1拮抗剂的2-氨基-4-芳基噻唑化合物 | |
| CN101827848B (zh) | 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物 | |
| CN103797010B (zh) | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 | |
| TWI592413B (zh) | 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物 | |
| CN118908978A (zh) | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 | |
| CN110088099A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 | |
| CN108698992A (zh) | 用于治疗癌症的2-氰基异吲哚啉衍生物 | |
| CN108602805A (zh) | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 | |
| CN116096719B (zh) | 作为alk5抑制剂的哒嗪基氨基衍生物 | |
| CN110461842A (zh) | 作为tnf活性调节剂的稠合五环咪唑衍生物 | |
| CN105916857A (zh) | 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途 | |
| TWI686389B (zh) | 新穎化合物 | |
| CN107074804A (zh) | 咔唑衍生物 | |
| JP2024513227A (ja) | Ｎｅｋ７阻害剤 | |
| CN116768861A (zh) | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 | |
| TW201136939A (en) | Tricyclic compounds and PBK inhibitors containing the same | |
| CN114502533A (zh) | 苯磺酰胺衍生物及其用途 | |
| CN100439365C (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| CN116745268A (zh) | 苯磺酰胺衍生物及其用途 | |
| CN108349989A (zh) | 吡喃并二吡啶化合物 | |
| CN102149706A (zh) | 4-氧代-l,4-二氢-喹啉的抗肿瘤的衍生物、其制备方法和其治疗用途 | |
| CN115536660A (zh) | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 | |
| WO2024140595A1 (zh) | 三环类化合物、其药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20160323 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |